109887-52-7

Usage

Uses

Used in Pharmaceutical Applications:
Trans-3-Ethoxycarbonyl-4-(4-flurophenyl)-N-methyl piperdine-2,6-dione is used as a pharmaceutical candidate for its potential biological activity. Its unique structural features may contribute to its efficacy in treating various medical conditions, although further research is required to determine its specific applications and mechanisms of action.
Used in Analytical Chemistry:
In the field of analytical chemistry, trans-3-Ethoxycarbonyl-4-(4-flurophenyl)-N-methyl piperdine-2,6-dione serves as a reference standard. Its well-defined chemical structure and properties make it suitable for use in calibration, quality control, and method development processes, ensuring accurate and reliable analytical results.
Used in Pharmacology Research:
Trans-3-Ethoxycarbonyl-4-(4-flurophenyl)-N-methyl piperdine-2,6-dione is utilized in pharmacology research to study its potential biological activity and therapeutic effects. Researchers can use trans-3-Ethoxycarbonyl-4-(4-flurophenyl)-N-methyl piperdine-2,6-dione to investigate its interactions with biological targets, evaluate its pharmacokinetics and pharmacodynamics, and assess its safety and efficacy in preclinical models.

InChI:InChI=1/C15H16FNO4/c1-3-21-15(20)13-11(8-12(18)17(2)14(13)19)9-4-6-10(16)7-5-9/h4-7,11,13H,3,8H2,1-2H3/t11-,13-/m1/s1

Upstream product

• 71510-95-7 2-carboethoxy-N-methyl-acetamide 
• 459-57-4 4-fluorobenzaldehyde 
• 391937-08-9 trans-3-ethoxycarbonyl-4(4'-fluorophenyl)piperidin-2,6-dione 
• 74-88-4 methyl iodide 
• 76311-95-0 methyl 3-(methylamino)-3-oxopropanoate 
• 459-32-5 (E)-4-fluorocinnamic acid 
• 459-32-5 4-fluorocinnamic acid 

Downstream Products

• 253768-88-6 (3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine-1-carboxylic acid phenyl ester 
• 110429-36-2 (3S,4R)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-1-methylpiperidine 

Relevant academic research and scientific papers

Improved process for paroxetine hydrochloride substantially free from potential impurities

An efficient process for production of paroxetine hydrochloride hemihydrate 1, a selective 5-hydroxytryptamine (serotonin) reuptake inhibitor, is described. Identification and control of potential impurities and establishment of efficient downstream workup procedures enabled us to produce paroxetine hydrochloride hemihydrate 1 efficiently.

A synthetic Sparrow west sandbank chiral intermediates

The invention discloses a method for synthesizing a paroxetine chiral intermediate, which comprises the following steps: reacting N-methyl malonic ester and a chiral fluorine cinnamate derivative under alkaline condition, after reaction is finished, post-treatment is carried out to obtain the paroxetine chiral intermediate. The method has the advantage that a chiral aminoalcohol compound is taken for synthesizing fluorine cinnamate as a chiral substrate, then an additive cyclization reaction is carried out with N-methyl malonic ester to obtain the chiral dioxopiperidine, the chiral aminoalcohol is simultaneously recovered, an useless enantiomer can be fully used during a paroxetine production process, environment pressure is reduced, reaction yield is high, operation is simple, raw material is easily available, reaction condition is mild, and post-treatment is simple. The reaction condition of the present invention can be used for massive preparation, the method is suitable for industrial production, and has high utility value and social economic benefit.

Catalytic Michael/Ring-Closure Reaction of α,β-Unsaturated Pyrazoleamides with Amidomalonates: Asymmetric Synthesis of (?)-Paroxetine

A highly enantioselective tandem Michael/ring-closure reaction of α,β-unsaturated pyrazoleamides and amidomalonates has been accomplished in the presence of a chiral N,N′-dioxide–Yb(OTf)3complex (Tf: trifluoromethanesulfonyl) to give various substituted chiral glutarimides with high yields and diastereo- and enantioselectivities. Moreover, this methodology could be used for gram-scale manipulation and was successfully applied to the synthesis of (?)-paroxetine. Further nonlinear and HRMS studies revealed that the real catalytically active species was a monomeric L-PMe2–Yb3+complex. A plausible transition state was proposed to explain the origin of the asymmetric induction.

Intermediate for synthesizing paroxetine and preparation method for intermediate and use of intermediate

The invention relates to the technical field of paroxetine, in particular to an intermediate for synthesizing paroxetine and a preparation method for the intermediate and use of the intermediate. The method comprises the specific step of reacting a compou

An efficient and stereoselective synthesis of (3S,4R)-(-)-trans-4- (4′-fluorophenyl)-3-hydroxymethyl-N-methylpiperidine

An asymmetric conjugate addition reaction between a chiral α,β-unsaturated amido ester and ethyl-N-methylmalonamide has been used as a key step in the synthesis of (3S,4R)-(-)-trans-4-(4′- fluorophenyl)-3-hydroxymethyl-N-methylpiperidine, a key intermediate for (-)-paroxetine.

Reduction compositions and processes for making the same

Novel reduction compositions are prepared from an active hydride, an additive, and a Lewis base in a hydrocarbon solvent. Such compositions can provide a superior reducing system for organic substrates.

NOVEL REDUCTION COMPOSITIONS AND PROCESSES FOR MAKING THE SAME

Novel reduction compositions are prepared from an active hydride, an additive, and a Lewis base in a hydrocarbon solvent. Such compositions can provide a superior reducing system for organic substrates.

PROCESS FOR STEREOSPECIFIC HYDROLYSIS OF PIPERIDINEDIONE DERIVATIVES

A process for stereospecifically hydrolysing a mixture of the (+) and (-) isomers of a compound of formula (II), in which R is C1-6 alkyl; using a carboxyl esterase enzyme, (i) to form a compound of formula (IIIA), and thereafter separating the resulting compound of formula (IIIA) from the remaining (-) isomer of formula (II); or (ii) to form a compound of formula (IIIB) and thereafter separating the resulting compound of formula (IIIB) from the remaining (+) isomer of formula (II).

Process for preparing aryl-piperidine carbinols and novel intermediates used in the process

A process is disclosed for the preparation of a compound of formula (I): STR1 wherein Ar is aryl or substituted aryl and R3 is hydrogen, alkyl or aralkyl, which process comprises reducing a compound of formula (II): STR2 wherein Ar and R3 are as defined with respect to formula (I) and R4 is alkyl. Compounds of formula (I) are useful as chemical intermediates.